1. Home
  2. Companies
  3. ILA
  4. Material Events

Island Pharmaceuticals (ASX:ILA) — Material Events

ASX:ILA · 37 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 2 articles Significant 29 articles Notable 6 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
29
Island Pharmaceuticals Partners with Texas Biomed to Sharpen Galidesivir Dose Ahead of Pivotal Marburg StudyMedium
Island Pharmaceuticals advances Galidesivir dose optimisation with Texas Biomed for pivotal FDA Animal Rule study
13 July 2026 ·Regulatory Development Update ·85
FDA Sticks to November Deadline for Galidesivir Feedback Despite ShutdownMedium
FDA confirms timely response for Galidesivir approval pathway despite US shutdown
22 Oct 2025 ·Regulatory Update ·85
Island Pharmaceuticals Advances Galidesivir Acquisition with FDA Fast-Track in SightMedium
Island Pharmaceuticals advances Galidesivir acquisition and FDA fast-track approval with strong preclinical data and shareholder support
30 Oct 2025 ·Quarterly Activities Report ·85
Island Pharmaceuticals Secures Texas Biomed Pact to Propel Galidesivir FDA PathwayMedium
Island Pharmaceuticals inks key agreement with Texas Biomed to advance Galidesivir development
17 Dec 2025 ·ASX Announcement ·85
Island Pharmaceuticals Accelerates Galidesivir Acquisition, Eyes FDA Fast-TrackMedium
Island Pharmaceuticals completes Galidesivir acquisition early, targets fast-track FDA approval
31 July 2025 ·ASX Announcement ·85
Island Pharmaceuticals Secures $9M to Propel Galidesivir Toward FDA ApprovalMedium
Island Pharmaceuticals Raises $9M to Advance Galidesivir FDA Approval and US Government Stockpile Opportunities
4 Feb 2026 ·Capital Raising ·85
Galidesivir Secures US Orphan Drug Status for Marburg Virus ProphylaxisMedium
Galidesivir granted FDA Orphan Drug Designation for Marburg virus disease
17 June 2026 ·Regulatory Update ·85
Island Pharmaceuticals Advances Galidesivir Antiviral with Government Approvals and Clinical Data Plans Amid Urgent Ebola OutbreakMedium
Island Pharmaceuticals advances Galidesivir antiviral with government approvals and clinical data plans amid urgent Ebola outbreak
8 July 2026 ·Corporate Presentation ·85
Island Pharmaceuticals Seeks FDA Nod to Fast-Track Marburg AntiviralMedium
Island Pharmaceuticals submits FDA briefing to fast-track Galidesivir approval for Marburg
29 Sept 2025 ·Regulatory Update ·85
Island Pharmaceuticals Joins Forces with USAMRIID to Fast-Track Marburg Virus DrugMedium
Island Pharmaceuticals partners with USAMRIID and Geneva Foundation to fast-track Galidesivir approval for Marburg Virus
4 Mar 2026 ·ASX Announcement ·85
Island Pharmaceuticals Advances Galidesivir with FDA Backing and US PartnershipsMedium
Island Pharmaceuticals de-risks Galidesivir regulatory pathway, expands US patent, and strengthens US biodefense ties
27 Jan 2026 ·Quarterly Activities Report ·85
Island Pharmaceuticals Taps BioCryst Veteran to Boost Galidesivir’s US Biodefence PushMedium
Island Pharmaceuticals appoints Raymond Taylor to accelerate Galidesivir antiviral development and US Government engagement
21 May 2026 ·Executive Appointment ·85
Island Pharmaceuticals Advances Dual Antiviral Strategy with Dengue Trial Success and Galidesivir AcquisitionHigh
Island Pharmaceuticals reports positive dengue trial results, acquires Galidesivir antiviral program, and strengthens balance sheet
24 July 2025 ·Quarterly Activities Report ·85
Island Pharmaceuticals Expands Pipeline with Galidesivir Amid Rising LossesMedium
Island Pharmaceuticals reports widened loss, acquires Galidesivir antiviral program, advances clinical pipeline and secures $9M capital raise
25 Feb 2026 ·Appendix 4D Half-year report ·85
Island Pharmaceuticals Secures FDA Pathway and $9M to Advance Galidesivir for Marburg VirusMedium
Island Pharmaceuticals Advances Galidesivir with FDA Alignment, Strategic Partnerships, and $9M Funding
27 Apr 2026 ·Quarterly Activities Report ·85
Island Pharmaceuticals Secures FDA Meeting to Fast-Track Marburg Virus DrugMedium
Island Pharmaceuticals Granted FDA Type C Meeting to Advance Galidesivir Approval
19 Sept 2025 ·Regulatory Update ·85
Island Pharmaceuticals Broadens Antiviral Reach with Burnet CollaborationMedium
Island Pharmaceuticals expands antiviral pipeline via Burnet Institute collaboration targeting measles, chikungunya, and Ross River virus
9 Mar 2026 ·ASX Announcement ·80
Island Pharmaceuticals Secures US Patent for Galidesivir Covid-19 Treatment Through 2042Medium
Island Pharmaceuticals Secures US Patent for Galidesivir Covid-19 Treatment Through 2042
5 Dec 2025 ·ASX Announcement ·80
Island Pharmaceuticals Secures US Patent for Galidesivir to Combat Deadly FilovirusesMedium
Island Pharmaceuticals Secures US Patent for Galidesivir to Treat Filoviridae Viruses Through 2031
7 Jan 2026 ·Patent Grant Announcement ·80
Island Pharmaceuticals Clarifies FDA Feedback Impact and $9m Capital RaiseMedium
Island Pharmaceuticals confirms FDA feedback materiality, addresses ASX disclosure queries, and announces $9m placement
10 Feb 2026 ·ASX Aware Letter Response ·80
Island Pharmaceuticals Unveils Positive Phase 2a Dengue Trial Data for ISLA-101Medium
Island Pharmaceuticals presents positive Phase 2a dengue trial results at Asia Dengue Summit
16 June 2026 ·Investor Presentation ·75
Island Pharmaceuticals Raises $1M to Accelerate Antiviral Galidesivir’s US PushMedium
Island Pharmaceuticals secures $1M funding via option exercise to advance antiviral drug Galidesivir
3 Dec 2025 ·Capital Raising ·75
Island Pharmaceuticals Taps US Experts to Boost Biodefence EdgeMedium
Island Pharmaceuticals appoints US government affairs firm to boost biodefence engagement
20 Nov 2025 ·ASX Announcement ·75
Island Pharmaceuticals Advances Galidesivir Dose Study with USAMRIID CollaborationMedium
Island Pharmaceuticals expands CRADA with USAMRIID for Galidesivir Marburg dose optimisation study
10 June 2026 ·Cooperative Research Agreement Update ·75
Island Pharmaceuticals Strengthens US Biodefence Ties Ahead of Galidesivir TrialsMedium
Island Pharmaceuticals boosts US biodefense ties with senior appointment and MC2 roles ahead of Galidesivir FDA Animal Rule studies
19 May 2026 ·Corporate Appointment and Strategic Update ·75
Island Pharmaceuticals Advances Galidesivir with FDA Animal Rule Pathway and Biodefence FocusMedium
Island Pharmaceuticals advances Galidesivir antiviral with FDA Animal Rule pathway and biodefense focus
11 June 2026 ·Investor Presentation ·75
Island Pharmaceuticals Advances Galidesivir with Key FDA SubmissionMedium
Island Pharmaceuticals advances Galidesivir development with key FDA submission under Animal Rule pathway
4 Dec 2025 ·ASX Announcement ·75
Island Pharmaceuticals Advances Galidesivir with GMP Manufacturing for Pivotal Marburg StudyMedium
Island Pharmaceuticals begins GMP manufacturing of Galidesivir to support pivotal Marburg study and biodefence opportunities
4 June 2026 ·Operational Update ·75
Island Pharmaceuticals Seeks FDA Nod to Fast-Track Galidesivir for MarburgMedium
Island Pharmaceuticals lodges FDA meeting request to fast-track Galidesivir approval for Marburg
1 Sept 2025 ·Regulatory Update ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.